Researchers have found in a new study that Children with mucopolysaccharidosis (MPS) undergoing adenotonsillectomy (AT) ...

JCR announced the launch of a film featured in The Next Frontier, a series presented by BIO and produced by BBC StoryWorks ...

Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries. With one FDA-approved drug, the pipeline ...

JCR Pharma introduces mucopolysaccharidosis type II disease awareness film featured in the Next Frontier series: Hyogo, Japan Friday, June 20, 2025, 18:00 Hrs [IST] JCR Pharmaceut ...

As part of the series, the JCR-sponsored film tells the story of a family affected by mucopolysaccharidosis type II (MPS II, or Hunter syndrome), a rare, progressive, life-threatening lysosomal ...

(MENAFN- GlobeNewsWire - Nasdaq) Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries.

The patients have conditions such as Fabry disease, Gaucher disease or mucopolysaccharidosis — inherited disorders caused by ...

DataM Intelligence | competitive Intelligence MPS I market evolution accelerates as gene therapies and BBB-penetrant ERTs emerge, challengi ...

Fintel reports that on June 20, 2025, William Blair downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...